Drug Analysis Service and Cannabis Laboratory
Health Canada’s Drug Analysis Service and Cannabis Laboratory analyze drugs and substances submitted by Canadian law enforcement and public health officials.
- Last updated: 2024-04-12
At-a-glance reports
At-a-glance: New psychoactive substances in Canada – 2022 New
The aim of this report is to describe new psychoactive substances that emerged in Canada in 2022 based on samples submitted to the Drug Analysis Service by law enforcement agencies and public health partners.
At-a-glance: The emergence of Nitazenes and Brorphine in Canada since 2019
This report aims at presenting the result of a pilot project based on a collaborative work between the Drug Analysis Service, the Canada Border Services Agency (CBSA) and the Royal Canadian Mounted Police (RCMP) related to Nitazenes and Brorphine in order to draw a more complete picture of the situation in Canada.
Infosheet
Emergence of Desalkylgidazepam, a novel benzodiazepine in Canada New
This short report provides quick statistics on Desalkylgidazepam, the most identified new psychoactive substance in Canada in 2022 based on samples submitted to the Drug Analysis Service by law enforcement agencies and public health partners.
Spotlight reports
Spotlight: The evolution of Fentanyl in Canada over the past 11 years
The aim of this spotlight report is to characterize trends in Fentanyl identifications across Canada since 2012 and draw a more comprehensive picture of Fentanyl in Canada based on exhibits seized and submitted to the Drug Analysis Service for analysis by law enforcement agencies.
Spotlight: The emergence of Xylazine in Canada
The aim of this spotlight report is to characterize trends in Xylazine identifications across Canada since 2012 and draw a more comprehensive picture of Xylazine in Canada based on exhibits seized and submitted to the Drug Analysis Service for analysis by law enforcement agencies.
- Date modified: